The European Medicines Agency is changing its assessment processes to share work more evenly among member states when it relocates because of Brexit.
Medicines assessments carried out by EU member state health authorities for the EMA will be done by several countries working together in future, rather than individual countries working alone as has been the case up to now, the news website Pharmaceutical Technology Europe has reported.
An EMA spokeswoman told the website that the change was a response to the challenges presented by the UK leaving the EU, which is forcing the EMA to relocate from London and to redistribute the work carried out by the UK’s Medicines and Healthcare products Regulatory Agency. The MHRA has been conducting 30-40 per cent of EMA assessments.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.